These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 22621380

  • 21. Enalapril dosage in steroid-resistant nephrotic syndrome.
    Bagga A, Mudigoudar BD, Hari P, Vasudev V.
    Pediatr Nephrol; 2004 Jan; 19(1):45-50. PubMed ID: 14648339
    [Abstract] [Full Text] [Related]

  • 22. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 23. Primary FSGS in Nephrotic Adults: Clinical Profile, Response to Immunosuppression and Outcome.
    Bagchi S, Agarwal S, Kalaivani M, Bhowmik D, Singh G, Mahajan S, Dinda A.
    Nephron; 2016 Jul; 132(2):81-5. PubMed ID: 26799973
    [Abstract] [Full Text] [Related]

  • 24. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 25. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
    [Abstract] [Full Text] [Related]

  • 26. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic.
    Stiles KP, Abbott KC, Welch PG, Yuan CM.
    Clin Nephrol; 2001 Aug; 56(2):89-95. PubMed ID: 11522100
    [Abstract] [Full Text] [Related]

  • 27. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
    Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.
    Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
    [Abstract] [Full Text] [Related]

  • 28. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 29. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
    Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE.
    J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A.
    Am J Kidney Dis; 2009 May; 53(5):760-9. PubMed ID: 19268410
    [Abstract] [Full Text] [Related]

  • 31. Losartan and enalapril are comparable in reducing proteinuria in children.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C.
    Kidney Int; 2012 Oct; 82(7):819-26. PubMed ID: 22739977
    [Abstract] [Full Text] [Related]

  • 32. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P, Fairley KF, Packham D.
    Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
    [Abstract] [Full Text] [Related]

  • 33. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors.
    Litwin M, Grenda R, Sladowska J, Antoniewicz J.
    Pediatr Nephrol; 2006 Nov; 21(11):1716-22. PubMed ID: 16909244
    [Abstract] [Full Text] [Related]

  • 34. Difficult-to-treat nephrotic syndrome: management and outcome.
    Sumboonnanonda A, Chongchate N, Suntornpoch V, Pattaragarn A, Supavekin S.
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S142-8. PubMed ID: 16856434
    [Abstract] [Full Text] [Related]

  • 35. Focal segmental glomerulosclerosis complicating solitary kidney.
    Oshiro Y, Umena S, Noda M.
    Clin Exp Nephrol; 2009 Feb; 13(1):81-4. PubMed ID: 18688570
    [Abstract] [Full Text] [Related]

  • 36. Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
    Chandar J, Abitbol C, Montané B, Zilleruelo G.
    Nephrol Dial Transplant; 2007 May; 22(5):1332-7. PubMed ID: 17299000
    [Abstract] [Full Text] [Related]

  • 37. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 38. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children.
    Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP.
    Nephrol Dial Transplant; 2008 Mar; 23(3):910-3. PubMed ID: 18039644
    [Abstract] [Full Text] [Related]

  • 39. [RAS blockade].
    Jin C, Ito S.
    Nihon Rinsho; 2004 Oct; 62(10):1880-4. PubMed ID: 15500134
    [Abstract] [Full Text] [Related]

  • 40. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
    Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S.
    Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.